View ValuationIntegral Diagnostics 향후 성장Future 기준 점검 3/6Integral Diagnostics (는) 각각 연간 31.3% 및 9.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 31.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.3% 로 예상됩니다.핵심 정보31.3%이익 성장률31.15%EPS 성장률Healthcare 이익 성장18.3%매출 성장률9.8%향후 자기자본이익률9.29%애널리스트 커버리지Good마지막 업데이트01 Dec 2025최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 25+ 1 more updateIntegral Diagnostics Limited Announces Executive ChangesIntegral Diagnostics Limited announced referred to its market release on 10 November 2025 announcing the appointment of Jason Martinez as the Company's new Managing Director and Chief Executive Officer. That release noted that Mr. Martinez's commencement date would subsequently be confirmed to the market. IDX advises that Mr. Martinez will commence in his role with IDX on 6 August 2026, following an extended garden leave period with his former employer. Dr Ian Kadish will continue serving as Managing Director and Chief Executive Officer until Mr. Martinez commences to ensure a seamless leadership transition for IDX.공시 • Feb 25+ 1 more updateIntegral Diagnostics Limited Declares A Franked Ordinary Dividend for the Six-Month Period Ended 31 December 2025, Payable on 2 April 2026Integral Diagnostics Limited has declared a franked ordinary dividend of AUD 0.033 per share for the six-month period ended 31 December 2025. The ex-date for the dividend is 4 March 2026, the record date is 5 March 2026, and the payment date is scheduled for 2 April 2026.공시 • Jan 15+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2026 Results on Aug 25, 2026Integral Diagnostics Limited announced that they will report fiscal year 2026 results on Aug 25, 2026공시 • Sep 02Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025.공시 • Mar 11Private Equity Players Reportedly Keep Close Tabs on Integral DiagnosticsIntegral Diagnostics Limited (ASX:IDX) is believed once again to be in the spotlight for private equity buyers after its share price took a hit after its half year results, trimming its market value to $837 million. Sources say the diagnostic imaging company is constantly being assessed by private equity firms, eager to increase exposure to healthcare. But right now it is looking like a good buying opportunity and is grabbing attention. Obvious suitors would be the underbidders from the sale last year of the Healius diagnostic imaging group that sold for $965 million to Affinity Equity Partners. The underbidders were TPG Capital, L.P. and Pacific Equity Partners.공시 • Feb 05Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive DirectorIntegral Diagnostics Limited announced the appointment of experienced IDX radiologist Dr. Manish Mittal (MBBS (Hons), MD, FRCR, FRANZCR, FSCMR) to the Board as a Radiologist Executive Director with effect from 5 February 2025. Mittal is a Fellow of both the UK and Australia & New Zealand Royal Colleges of Radiology with a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. Dr. Mittal has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units. He is currently the Clinical Director of IDXt, IDX's fast growing teleradiology business, and also a consultant radiologist at Gold Coast University Hospital.공시 • Jan 20Integral Diagnostics Limited Announces Company Secretary ChangesIn accordance with Listing Rule 3.16, Integral Diagnostics Limited announced that effective 20 January 2025, Mr. John Merity has been appointed as company's permanent Company Secretary, continuing from the interim role to which he was appointed on 7 June 2024. Also effective from 20 January 2025, Ms Nikki Dalla Valle will relinquish her role as Company Secretary, continuing in her role as General Counsel, responsible for Legal and Risk.공시 • Dec 20Integral Diagnostics Limited Announces Board AppointmentsIntegral Diagnostics Limited has appointed the following Capitol Directors to the Integral Board with effect from 20 December 2024. Laura McBain, as Non-Executive Director; and Dr Kevin Shaw, as Non-Executive Director. Ms McBain has extensive executive and leadership experience having held roles as Managing Director at Bellamy's Australia, Maggie Beer Holdings and Lark Distilling. Dr Shaw is a highly qualified radiologist with fellowship training in MRI. He is the Director of Medical Imaging at University Hospital Geelong.공시 • Dec 12Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. As of October 29, 2024, Capitol announces that the Federal Court of Australia (Court) has today made orders to postpone the date of the Scheme Meeting at which Capitol Shareholders will vote on the proposed Scheme. The Scheme Meeting has been postponed from October 31, 2024 to December 2, 2024. The date for the Second Court Hearing has been changed from November 1, 2024 to December 4, 2024. As a consequence of the Court orders postponing the Scheme Meeting, the indicative Effective Date on which the Scheme comes into effect and is binding on Capitol Shareholders will be on December 5, 2024. As of November 25, 2024, the Scheme is subject to a number of conditions precedent, including that IDX has received informal merger clearance from the Australian Competition and Consumer Commission (ACCC). The ACCC has delayed its proposed decision date in relation to the Competition Approval to allow the ACCC to consider the divestment. The ACCC has not yet announced a new proposed date of its decision in relation to the Competition Approval, although Capitol anticipates that the decision date will occur in December 2024. The Scheme Meeting will proceed on December 2, 2024. As of December 10, 2024, the Australian Competition and Consumer Commission confirmed that it will not oppose the merger and the Federal Court of Australia made orders approving the Scheme. The deal is expected to complete on December 11, 2024. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors to Integral Diagnostics Limited (ASX:IDX) while Citigroup Global Markets Australia Pty Limited acted as a financial advisor to Capitol Health Limited. Herbert Smith Freehills acted as a legal advisor to Integral Diagnostics Limited while Maddocks Inc. Pty Ltd. provided legal assistance to Capitol Health Limited. KPMG Financial Advisory Services (Australia) Pty Limited provided fairness opinion in the deal to Capitol Health Limited. Computershare Investor Services Pty Limited acted as registrar to Integral Diagnostics Limited and Capitol Health Limited. Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ) on December 11, 2024.공시 • Nov 08+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Integral Diagnostics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025공시 • Jun 19Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors and Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Citigroup Global Markets Australia Pty Limited acted as financial advisor and Maddocks Inc. Pty Ltd. acted as legal advisor to Capitol Health Limited.공시 • Feb 07IDX™ Announces Appointment of Scott Paterson as Worldwide CFOIDX™ announced the appointment of industry veteran Scott Paterson as chief financial officer. In his role, Paterson will partner with Worldwide CEO Myles Peacock and the IDX Board of Directors to continue the growth and evolution of the business. Paterson has held various senior finance roles for over 15 years, with many spent in marketing content, communications and technology. Prior to joining IDX, Paterson was CFO of private equity-backed TREND Networks, where he played a key role in the growth of the organization. He subsequently led the business through a private equity exit. Prior to TREND Networks, Paterson was group financial controller at Guinness World Records, where he was integral in transforming the business from its publishing core to a more diversified media enterprise focused on content creation and both digital and broadcast media. Paterson’s appointment is effective immediately.공시 • Dec 20+ 2 more updatesIntegral Diagnostics Limited, Annual General Meeting, Nov 01, 2024Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024.공시 • Dec 12Integral Diagnostics Limited Announces Change of Company SecretaryIntegral Diagnostics Limited advised that Kirsty Lally has resigned as Company Secretary of Integral Diagnostics Limited effective 14 December 2023. Nikki Dalla Valle has been appointed as Company Secretary effective 14 December 2023 and is the person nominated under Listing Rule 12.6 for communication with ASX in relation to Listing Rule matters.공시 • Nov 30Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023Integral Diagnostics Limited announced resignation of Helen Kurincic as director effective 29 November 2023.공시 • Sep 28Integral Diagnostics Limited Appoints Toby Hall as DirectorIntegral Diagnostics Limited announced that the appointment of Toby Hall as director. The date of appointment is September 28, 2023.공시 • Sep 25Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023Integral Diagnostics Limited declared a fully franked final dividend of AUD 0.03500000 per ordinary share for the six months ended June 30, 2023 with a record date of 1 September 2023. Ex date of August 31, 2023.Payable on 4 October 2023.공시 • Aug 28Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023On 28 August 2023 the directors of Integral Diagnostics Limited declared a fully franked final dividend of 3.5 cents per ordinary share with a record date of 1 September 2023 to be paid on 4 October 2023.공시 • Aug 10Integral Diagnostics Limited Announces Board ChangesIntegral Diagnostics Limited announced the appointment of Ingrid Player as an independent non-executive Director, effective 29 August 2023. Ms. Player has more than 20 years' experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms. Player was Group Executive - Legal, Governance and Sustainability at Healthscope. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board extensive experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd, Cogstate Ltd, Epworth Foundation and HealthShare Victoria. She holds a Bachelor of Laws (Hons) and Bachelor of Economics from Monash University and is a member of the AICD. She will be appointed a Member of the Audit, Risk & Compliance Committee and a Member of the People, Culture & Remuneration Committee. The company announced the resignation of John Atkin as an independent non-executive Director effective 31 August 2023. The company also announced the resignation of Dr. Nazar Bokani, an Executive Radiologist Director effective 9 August 2023. Dr. Bokani joined the Board on 26 April 2021 and is relocating overseas to be closer to his family.공시 • Feb 18Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023Integral Diagnostics Limited announced an ordinary dividend of AUD 0.025000 for the six months ended December 31, 2022. The ex-date is March 2, 2023, record date is March 3, 2023, and payment date is April 4, 2023.공시 • Feb 16Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023Integral Diagnostics Limited announced that they will report first half, 2023 results on Feb 17, 2023공시 • Jan 09Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023.이익 및 매출 성장 예측OTCPK:ITGD.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/2028908697714886/30/20278555868135106/30/20268054868120106/30/202562751474N/A3/31/202555952473N/A12/31/202449163473N/A9/30/2024481-283870N/A6/30/2024470-614266N/A3/31/2024463-592962N/A12/31/2023456-581658N/A9/30/2023449-162063N/A6/30/2023441252367N/A3/31/2023418232056N/A12/31/2022395211745N/A9/30/2022378181341N/A6/30/202236115937N/A3/31/2022361181441N/A12/31/2021360221844N/A9/30/2021356263457N/A6/30/2021351314970N/A3/31/2021333325473N/A12/31/2020315325976N/A9/30/2020295284465N/A6/30/2020276232854N/A3/31/2020263221947N/A12/31/201925021939N/A9/30/2019241211237N/A6/30/2019232211534N/A3/31/201922219N/A30N/A12/31/201821117N/A26N/A9/30/201820016N/A26N/A6/30/201818915N/A27N/A3/31/201818715N/A27N/A12/31/201718515N/A27N/A9/30/201718215N/A25N/A6/30/201718015N/A23N/A3/31/201717716N/A26N/A12/31/201617516N/A30N/A9/30/201617114N/A27N/A6/30/201616811N/A24N/A3/31/201616511N/A22N/A12/31/201516211N/A20N/A9/30/20151578N/A18N/A6/30/20151515N/A17N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ITGD.F 의 연간 예상 수익 증가율(31.3%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: ITGD.F 의 연간 수익(31.3%)이 US 시장(16.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: ITGD.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: ITGD.F 의 수익(연간 9.8%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: ITGD.F 의 수익(연간 9.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ITGD.F의 자본 수익률은 3년 후 9.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/03 17:19종가2025/09/05 00:00수익2025/06/30연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Integral Diagnostics Limited는 21명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Thomas YeoBarrenjoey Markets Pty LimitedSaul HadassinBarrenjoey Markets Pty LimitedBenjamin BrayshawBarrenjoey Markets Pty Limited18명의 분석가 더 보기
공시 • Mar 25+ 1 more updateIntegral Diagnostics Limited Announces Executive ChangesIntegral Diagnostics Limited announced referred to its market release on 10 November 2025 announcing the appointment of Jason Martinez as the Company's new Managing Director and Chief Executive Officer. That release noted that Mr. Martinez's commencement date would subsequently be confirmed to the market. IDX advises that Mr. Martinez will commence in his role with IDX on 6 August 2026, following an extended garden leave period with his former employer. Dr Ian Kadish will continue serving as Managing Director and Chief Executive Officer until Mr. Martinez commences to ensure a seamless leadership transition for IDX.
공시 • Feb 25+ 1 more updateIntegral Diagnostics Limited Declares A Franked Ordinary Dividend for the Six-Month Period Ended 31 December 2025, Payable on 2 April 2026Integral Diagnostics Limited has declared a franked ordinary dividend of AUD 0.033 per share for the six-month period ended 31 December 2025. The ex-date for the dividend is 4 March 2026, the record date is 5 March 2026, and the payment date is scheduled for 2 April 2026.
공시 • Jan 15+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2026 Results on Aug 25, 2026Integral Diagnostics Limited announced that they will report fiscal year 2026 results on Aug 25, 2026
공시 • Sep 02Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025.
공시 • Mar 11Private Equity Players Reportedly Keep Close Tabs on Integral DiagnosticsIntegral Diagnostics Limited (ASX:IDX) is believed once again to be in the spotlight for private equity buyers after its share price took a hit after its half year results, trimming its market value to $837 million. Sources say the diagnostic imaging company is constantly being assessed by private equity firms, eager to increase exposure to healthcare. But right now it is looking like a good buying opportunity and is grabbing attention. Obvious suitors would be the underbidders from the sale last year of the Healius diagnostic imaging group that sold for $965 million to Affinity Equity Partners. The underbidders were TPG Capital, L.P. and Pacific Equity Partners.
공시 • Feb 05Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive DirectorIntegral Diagnostics Limited announced the appointment of experienced IDX radiologist Dr. Manish Mittal (MBBS (Hons), MD, FRCR, FRANZCR, FSCMR) to the Board as a Radiologist Executive Director with effect from 5 February 2025. Mittal is a Fellow of both the UK and Australia & New Zealand Royal Colleges of Radiology with a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. Dr. Mittal has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units. He is currently the Clinical Director of IDXt, IDX's fast growing teleradiology business, and also a consultant radiologist at Gold Coast University Hospital.
공시 • Jan 20Integral Diagnostics Limited Announces Company Secretary ChangesIn accordance with Listing Rule 3.16, Integral Diagnostics Limited announced that effective 20 January 2025, Mr. John Merity has been appointed as company's permanent Company Secretary, continuing from the interim role to which he was appointed on 7 June 2024. Also effective from 20 January 2025, Ms Nikki Dalla Valle will relinquish her role as Company Secretary, continuing in her role as General Counsel, responsible for Legal and Risk.
공시 • Dec 20Integral Diagnostics Limited Announces Board AppointmentsIntegral Diagnostics Limited has appointed the following Capitol Directors to the Integral Board with effect from 20 December 2024. Laura McBain, as Non-Executive Director; and Dr Kevin Shaw, as Non-Executive Director. Ms McBain has extensive executive and leadership experience having held roles as Managing Director at Bellamy's Australia, Maggie Beer Holdings and Lark Distilling. Dr Shaw is a highly qualified radiologist with fellowship training in MRI. He is the Director of Medical Imaging at University Hospital Geelong.
공시 • Dec 12Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. As of October 29, 2024, Capitol announces that the Federal Court of Australia (Court) has today made orders to postpone the date of the Scheme Meeting at which Capitol Shareholders will vote on the proposed Scheme. The Scheme Meeting has been postponed from October 31, 2024 to December 2, 2024. The date for the Second Court Hearing has been changed from November 1, 2024 to December 4, 2024. As a consequence of the Court orders postponing the Scheme Meeting, the indicative Effective Date on which the Scheme comes into effect and is binding on Capitol Shareholders will be on December 5, 2024. As of November 25, 2024, the Scheme is subject to a number of conditions precedent, including that IDX has received informal merger clearance from the Australian Competition and Consumer Commission (ACCC). The ACCC has delayed its proposed decision date in relation to the Competition Approval to allow the ACCC to consider the divestment. The ACCC has not yet announced a new proposed date of its decision in relation to the Competition Approval, although Capitol anticipates that the decision date will occur in December 2024. The Scheme Meeting will proceed on December 2, 2024. As of December 10, 2024, the Australian Competition and Consumer Commission confirmed that it will not oppose the merger and the Federal Court of Australia made orders approving the Scheme. The deal is expected to complete on December 11, 2024. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors to Integral Diagnostics Limited (ASX:IDX) while Citigroup Global Markets Australia Pty Limited acted as a financial advisor to Capitol Health Limited. Herbert Smith Freehills acted as a legal advisor to Integral Diagnostics Limited while Maddocks Inc. Pty Ltd. provided legal assistance to Capitol Health Limited. KPMG Financial Advisory Services (Australia) Pty Limited provided fairness opinion in the deal to Capitol Health Limited. Computershare Investor Services Pty Limited acted as registrar to Integral Diagnostics Limited and Capitol Health Limited. Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ) on December 11, 2024.
공시 • Nov 08+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Integral Diagnostics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025
공시 • Jun 19Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors and Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Citigroup Global Markets Australia Pty Limited acted as financial advisor and Maddocks Inc. Pty Ltd. acted as legal advisor to Capitol Health Limited.
공시 • Feb 07IDX™ Announces Appointment of Scott Paterson as Worldwide CFOIDX™ announced the appointment of industry veteran Scott Paterson as chief financial officer. In his role, Paterson will partner with Worldwide CEO Myles Peacock and the IDX Board of Directors to continue the growth and evolution of the business. Paterson has held various senior finance roles for over 15 years, with many spent in marketing content, communications and technology. Prior to joining IDX, Paterson was CFO of private equity-backed TREND Networks, where he played a key role in the growth of the organization. He subsequently led the business through a private equity exit. Prior to TREND Networks, Paterson was group financial controller at Guinness World Records, where he was integral in transforming the business from its publishing core to a more diversified media enterprise focused on content creation and both digital and broadcast media. Paterson’s appointment is effective immediately.
공시 • Dec 20+ 2 more updatesIntegral Diagnostics Limited, Annual General Meeting, Nov 01, 2024Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024.
공시 • Dec 12Integral Diagnostics Limited Announces Change of Company SecretaryIntegral Diagnostics Limited advised that Kirsty Lally has resigned as Company Secretary of Integral Diagnostics Limited effective 14 December 2023. Nikki Dalla Valle has been appointed as Company Secretary effective 14 December 2023 and is the person nominated under Listing Rule 12.6 for communication with ASX in relation to Listing Rule matters.
공시 • Nov 30Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023Integral Diagnostics Limited announced resignation of Helen Kurincic as director effective 29 November 2023.
공시 • Sep 28Integral Diagnostics Limited Appoints Toby Hall as DirectorIntegral Diagnostics Limited announced that the appointment of Toby Hall as director. The date of appointment is September 28, 2023.
공시 • Sep 25Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023Integral Diagnostics Limited declared a fully franked final dividend of AUD 0.03500000 per ordinary share for the six months ended June 30, 2023 with a record date of 1 September 2023. Ex date of August 31, 2023.Payable on 4 October 2023.
공시 • Aug 28Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023On 28 August 2023 the directors of Integral Diagnostics Limited declared a fully franked final dividend of 3.5 cents per ordinary share with a record date of 1 September 2023 to be paid on 4 October 2023.
공시 • Aug 10Integral Diagnostics Limited Announces Board ChangesIntegral Diagnostics Limited announced the appointment of Ingrid Player as an independent non-executive Director, effective 29 August 2023. Ms. Player has more than 20 years' experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms. Player was Group Executive - Legal, Governance and Sustainability at Healthscope. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board extensive experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd, Cogstate Ltd, Epworth Foundation and HealthShare Victoria. She holds a Bachelor of Laws (Hons) and Bachelor of Economics from Monash University and is a member of the AICD. She will be appointed a Member of the Audit, Risk & Compliance Committee and a Member of the People, Culture & Remuneration Committee. The company announced the resignation of John Atkin as an independent non-executive Director effective 31 August 2023. The company also announced the resignation of Dr. Nazar Bokani, an Executive Radiologist Director effective 9 August 2023. Dr. Bokani joined the Board on 26 April 2021 and is relocating overseas to be closer to his family.
공시 • Feb 18Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023Integral Diagnostics Limited announced an ordinary dividend of AUD 0.025000 for the six months ended December 31, 2022. The ex-date is March 2, 2023, record date is March 3, 2023, and payment date is April 4, 2023.
공시 • Feb 16Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023Integral Diagnostics Limited announced that they will report first half, 2023 results on Feb 17, 2023
공시 • Jan 09Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023.